● ImportantWorld24 outlets covering this

Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

First publishedAug 19, 10:49 UTC
Last updatedAug 20, 13:37 UTC · 11m ago
11 outletCNBC Top News33 outletsInvesting.com · Stock Market, MarketWatch11 outletNBC News11 outletTIME33 outletsNYT Home, The Hill, CBS News11 outletSeattle Times33 outletsNBC News, Ars Technica, New York Post22 outletsSeattle Times, Fortune11 outletMarketWatch11 outletAxios11 outletAl Jazeera11 outletNBC News11 outletCBS News22 outletsCBS News11 outletBBC US & Canada11 outletNPR Health
CNBC Top News7Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trialOpen ↗Investing.com · Stock Market6Moderna shares surge as melanoma vaccine with Merck succeeds in large trialOpen ↗Investing.com · Stock Market6Moderna shares soar over 90% on melanoma drug trial successOpen ↗MarketWatch7Moderna’s stock doubles on promising cancer-vaccine resultsOpen ↗NBC News8Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanomaOpen ↗TIME7Promising Results for mRNA Cancer Vaccine from Moderna and MerckOpen ↗NYT Home9Moderna, Merck Say mRNA Vaccine Prevents Melanoma From ReturningOpen ↗The Hill7Moderna, Merck mRNA cancer vaccine prevents melanoma from returningOpen ↗CBS News8Moderna stock surges as melanoma vaccine trial shows "landmark moment"Open ↗Seattle Times6Moderna shares surge after it says its experimental mRNA cancer treatment passed a key testOpen ↗NBC News8Merck and Moderna say cancer vaccine shows signs of preventing recurrence of melanomaOpen ↗Ars Technica7mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck sayOpen ↗New York Post5New vaccine prevents deadliest skin cancer from coming back: drugmakersOpen ↗Seattle Times6A new mRNA vaccine could prevent melanoma from returningOpen ↗Fortune6Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaringOpen ↗MarketWatch7Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rallyOpen ↗Axios7Moderna and Merck shares soar on mRNA cancer vaccineOpen ↗Al Jazeera7Moderna, Merck unveil mRNA-based cancer vaccine that cuts spreadOpen ↗NBC News8Potential new skin cancer vaccineOpen ↗CBS News8Experimental melanoma vaccine shows promising resultsOpen ↗CBS News8Moderna reaches "landmark moment" in Melanoma vaccine trialOpen ↗CBS News8How Moderna's melanoma mRNA vaccine could fight deadliest skin cancerOpen ↗BBC US & Canada9Vaccine trialled by Moderna and Merck stops skin cancer returningOpen ↗NPR Health8New mRNA vaccine could reduce the recurrence and spread of skin cancerOpen ↗
24 outlets over time — hover a bar for its window & outletslast updated
● Story signals

How strong is this topic?

8.7/10Significanceimpact & urgency
7.2/10Source trustoutlet authority
24Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

A new jab extended the length of time patients were cancer free, but it is unclear for how long.

Reported by 24 outlets BBC US & Canada, NYT Home, NPR Health, CBS News, NBC News, and 11 more. See all sources ↓

Read the full report at BBC US & Canada

Why it matters

24 outlets are covering this world story — one to watch as reporting develops.

In brief
What's the story?
A new jab extended the length of time patients were cancer free, but it is unclear for how long.
How widely is it covered?
24 outlets, average source rating 7.2/10.
When was it last updated?
11m ago.
Different angles across outlets
Coverage map

How outlets are framing the same story

Here's how each outlet is covering the story — compare their headlines and timing at a glance.

  • Coverage card16 outlets
    1Coverage
    Scouting report

    Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

    Sources16
    TypeCoverage
    BBC US & Canada
    NYT Home
    NPR Health
    CBS News
    NBC News
    Al Jazeera
    Axios
    MarketWatch
    Ars Technica
    The Hill
    TIME
    CNBC Top News
    Fortune
    Seattle Times
    Investing.com · Stock Market
    New York Post
Related in the knowledge graph
Sources (24)
Avg source rating 7.2/10
Processing cluster
A1A2A3B1B2B3
Share this article
Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)